Related Experiment Video

Updated: Apr 20, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.8K

Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions

Abhishek Tripathi1, Charles G Drake, Lauren C Harshman

  • 1Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|December 3, 2014
PubMed

Insights

Programmed cell death-1 (PD-1) blockade shows promise in treating renal cell carcinoma by enhancing antitumor immunity. This approach is well-tolerated and suitable for combination therapies, with PD-L1 expression as a potential biomarker.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Programmed cell death-1 (PD-1) is an immune checkpoint receptor upregulated on tumor-infiltrating T cells.
  • Upregulated PD-1 provides an inhibitory signal, contributing to tumor immune escape.
  • Blocking PD-1 interactions with its ligands (PD-L1/PD-L2) aims to restore antitumor immune responses.

Purpose of the Study:

  • To review the biological basis, preclinical data, and clinical trials of targeting the PD-1 pathway in renal cell carcinoma.
  • To discuss the potential of PD-1 blockade as a monotherapy and in combination strategies.
  • To explore the role of PD-L1 expression as a predictive biomarker.

Main Methods:

  • Literature review of preclinical studies and ongoing clinical trials.
  • Analysis of the mechanism of action of PD-1 blocking antibodies.
  • Evaluation of combination strategies with targeted therapies and other immunotherapies.

Main Results:

  • PD-1 blockade has demonstrated encouraging initial results with durable responses in renal cell carcinoma patients.
  • The treatment exhibits an acceptable toxicity profile, supporting its use in combination therapies.
  • PD-L1 expression is under investigation as a predictive biomarker for treatment response.

Conclusions:

  • Targeting the PD-1 pathway is a promising strategy for renal cell carcinoma treatment.
  • PD-1 blockade's tolerability facilitates combination with tyrosine kinase inhibitors, anti-VEGF antibodies, and other immunotherapies.
  • Further research is needed to address challenges and optimize PD-1 pathway targeting in renal cell carcinoma.

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.7K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.4K